These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2248 related articles for article (PubMed ID: 25442674)
1. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
2. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457 [TBL] [Abstract][Full Text] [Related]
3. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692 [TBL] [Abstract][Full Text] [Related]
4. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma. Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736 [TBL] [Abstract][Full Text] [Related]
5. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets. Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD Cells; 2024 Feb; 13(5):. PubMed ID: 38474373 [TBL] [Abstract][Full Text] [Related]
6. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909 [TBL] [Abstract][Full Text] [Related]
7. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma. Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046 [TBL] [Abstract][Full Text] [Related]
8. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924 [TBL] [Abstract][Full Text] [Related]
9. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612 [TBL] [Abstract][Full Text] [Related]
10. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma. Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088 [TBL] [Abstract][Full Text] [Related]
11. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis. Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809 [TBL] [Abstract][Full Text] [Related]
12. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069 [TBL] [Abstract][Full Text] [Related]
13. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Wysocki PJ Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082 [TBL] [Abstract][Full Text] [Related]
14. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177 [TBL] [Abstract][Full Text] [Related]
15. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032 [TBL] [Abstract][Full Text] [Related]
16. Cellular and molecular effects of the mTOR inhibitor everolimus. Saran U; Foti M; Dufour JF Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617 [TBL] [Abstract][Full Text] [Related]
17. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261 [TBL] [Abstract][Full Text] [Related]
18. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Mi W; Ye Q; Liu S; She QB Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827 [TBL] [Abstract][Full Text] [Related]
19. Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma. Amin AG; Jeong SW; Gillick JL; Sursal T; Murali R; Gandhi CD; Jhanwar-Uniyal M Int J Oncol; 2021 Oct; 59(4):. PubMed ID: 34523696 [TBL] [Abstract][Full Text] [Related]
20. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). Feldman ME; Shokat KM Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]